BIOGEN (BIIB): Free Stock Analysis Report This article Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Dealoriginally appeared on Benzinga.com ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.

SWOT Analysis Published02/18/2025, 05:33 AM Biogen's SWOT analysis: stock faces challenges amid pipeline potential View all comments (0)0 BIIB -2.42% ...

Biogen's pipeline has faced recent setbacks, including the discontinuation of SAGE-324 (BIIB124) for essential tremor following disappointing Phase 2 results.

Jefferies writes the company may seek to acquire “tuck-in” specialty commercial areas. Biogen faced several pipeline setbacks in 2024, including programs for ALS, tremor, and Angelman syndrome.

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030. Challenges like ...

Company News Published11/05/2024, 09:18 AM Biogen's SWOT analysis: stock outlook amid pipeline challenges, market shifts View all comments (0)0 BIIB - ...

Biogen ended 2023 with $5.9 billion in net debt, but with free cash flow likely to return to over $2 billion annually by 2025, we think the firm is in a solid financial position. The $7.3 billion ...

Ami Fadia has given his Buy rating due to a combination of factors pertaining to Biogen’s strategic progress in the Alzheimer’s Disease (AD) market and the development of their drug pipeline.